BRIEF—Hikma inks MENA deal for Baxdela

London-listed Hikma Pharmaceuticals has entered into an exclusive license, supply and distribution agreement with Melinta Therapeutics for the latter’s intravenous and oral formulations of Baxdela (delafloxacin) across all its MENA markets. In addition, Hikma has the right of first negotiation for all other products in Melinta’s portfolio and pipeline in the region.

Baxdela is a novel antibiotic product used for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). Baxdela is a fluoroquinolone with demonstrated efficacy against both gram-positive and gram-negative pathogens, including MRSA (methicillin-resistant Staphylococcus aureus).Baxdela was approved by the US Food and Drug Administration in 2017.

Mazen Darwazah, executive vice chairman and president of MENA, said: “We are very pleased to establish a partnership with Melinta and to be able to bring this innovative product to the region. As the challenge of AMR grows, we have an important role to play in helping to equip doctors here in MENA with the latest and most innovative developments.”